MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC

Topline Phase III data for AstraZeneca's PD-L1 inhibitor Imfinzi in NSCLC have overshadowed the group's second quarter earnings – but not in a good way. Positive Tagrisso data from the Phase III FLAURA trial reported at the same time were not enough to stem the stock bleed.